| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04387240 Details | 2022-05-02 Interventional | 2 | 0 | Artemisinin Artemisinins Artesunate COVID-19 Coronavirus Inf… Corona Virus In… Covid 19 Positi… | did not get enough fund and IRB request - | |||
| NCT04331717 Details | 2022-05-02 Interventional | 2 | 0 | Leuprolide Obesity, Morbid Prostate Adenoc… | accrual on hold - | |||
| NCT03320642 Details | 2022-05-02 Interventional | 1 | 84 | Calcineurin Inh… Graft vs Host D… Hematologic Neo… Hematologic Mal… | Study terminated by sponsor - | |||
| NCT01608451 Details | 2022-05-02 Interventional | 3 | 800 | Cholecalciferol Progesterone Vitamin D Breast Neoplasm… Locally Advance… | Slow accrual implies that clinical questions being questioned have lost its significance. - | |||
| NCT04042727 Details | 2022-04-29 Interventional | 2/3 | 13 | Dexmedetomidine Atrial Fibrilla… Heart Rate Cont… Rapid Atrial Fi… | Futility, as a result of CIVID-19 impact - | |||
| NCT02940548 Details | 2022-04-29 Interventional | 4 | 99 | Amlodipine Nifedipine Hypertension | The patient recruitment and follow-ups were influenced with the pandemic of COVID-19 - | |||
| NCT00358163 Details | 2022-04-29 Interventional | 1 | 7 | Paclitaxel Vatalanib Neoplasms Metastatic Non-… | - - | |||
| NCT02711137 Details | 2022-04-28 Interventional | 1/2 | 137 | Azacitidine Gemcitabine INCB057643 Paclitaxel Rucaparib Neoplasms Solid Tumors | Study terminated due to safety issues. - | |||
| NCT01264679 Details | 2022-04-28 Interventional | 3 | 8 | Ferrosoferric O… Anemia Anemia, Iron-De… Deficiency Dise… Iron Deficienci… Kidney Diseases Renal Insuffici… Iron Deficiency… | Several factors contributed to significant challenges in enrollment and led the Sponsor to
discontinue the AMAG-FER-CKD-253 study as designed. While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible. | |||
| NCT01155388 Details | 2022-04-28 Interventional | 3 | 14 | Ferrosoferric O… Ferrous fumarat… Anemia Anemia, Iron-De… Deficiency Dise… Iron Deficienci… Kidney Diseases Renal Insuffici… Iron Deficiency… Nondialysis-dep… | Several factors contributed to significant challenges in enrollment and led the Sponsor to
discontinue the AMAG-FER-CKD-252 study as designed. While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible. | |||
| NCT03254732 Details | 2022-04-27 Interventional | 1 | 33 | Pembrolizumab Advanced Solid … | Changing Corporate Priorities - | |||
| NCT02154529 Details | 2022-04-27 Interventional | 1/2 | 17 | Trastuzumab XL647 Breast Neoplasm… Neoplasms HER-2 Positive … Metastatic Mali… | Sponsor closed the study due to lack of response. - | |||
| NCT00707213 Details | 2022-04-27 Interventional | 1 | 19 | Deoxyglucose Febrile Neutrop… Neutropenia Cancer | Funding from the NIH ended and not all patients had been accrued - | |||
| NCT03172897 Details | 2022-04-26 Interventional | 4 | - | Dexmedetomidine Delirium Adult Disease Dexmedetomidine Intensive Care … Mechanical Vent… | The trial was stopped because of difficulty in recruiting patients (another trial had similar
inclusion/exclusion criteria). No patients was recruited in this trial. - | |||
| NCT04371393 Details | 2022-04-25 Interventional | 3 | 223 | Remestemcel-l Acute Lung Inju… Respiratory Dis… Respiratory Dis… Syndrome Acute Respirato… COVID Mesenchymal Str… Remestemcel-L | At 3d interim analysis, randomization, but not follow-up, was halted by the DSMB due to low
predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative
mortality reduction) were the trial to complete randomization. - | |||
| NCT04003818 Details | 2022-04-25 Interventional | 4 | 50 | Teicoplanin Clostridium Inf… Colitis Diarrhea Infections Clostridium Dif… | Due to COVID-19 and great challenges during patient enrolment period, current status of this
study is far behind the plan. The study cannot be completed according to the plan. Sanofi
decides to terminate the study upon comprehensive assessment. - | |||
| NCT03761134 Details | 2022-04-25 Interventional | 3 | 377 | (2S,3R,4R,5S,6R… Metformin Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to
transfer sponsorship during the conduct of ongoing studies. - | |||
| NCT03760965 Details | 2022-04-25 Interventional | 3 | 276 | (2S,3R,4R,5S,6R… Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to
transfer sponsorship during the conduct of ongoing studies. - | |||
| NCT03630809 Details | 2022-04-25 Interventional | 2 | 16 | Vaccines Breast Neoplasm… Breast Neoplasm… Breast Cancer Breast Cancer F… Breast Cancer, … HER-2 Gene Ampl… HER-2 Protein O… HER2 Positive B… HER2-positive B… | Quality of the data originating from prior versions of the protocol has been affected by
protocol deviations triggered by the COVID-19 pandemics - | |||
| NCT03555968 Details | 2022-04-25 Interventional | 4 | 0 | Dronabinol Alcohol Drinkin… Accident, Traff… Cannabis | Logistical issues - |